Paratus Sciences develops human therapeutics by studying the unique evolutionary adaptations found in bats. The company utilizes a discovery platform merging genomics and informatics to identify promising therapeutic targets from bat biology. This research focuses on creating novel treatments for immunological, inflammatory, and cardiometabolic conditions.
Funding
$100M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AVCECLBFounders
Product
Problem
Many immunological, inflammatory, and cardiometabolic diseases lack effective treatments, resulting in significant unmet medical needs. Identifying novel therapeutic targets for these conditions remains a challenge due to the complexity of human biology and disease mechanisms.
Solution
Paratus Sciences leverages bat genomics and informatics to identify unique therapeutic targets for human diseases. By studying the evolutionary adaptations of bats, the company aims to develop therapies that mimic bats' natural resistance to certain diseases. Their discovery platform combines genomics and informatics to analyze bat DNA, focusing on immunological, inflammatory, and cardiometabolic conditions. The company's approach seeks to translate evolutionary insights into effective treatments for diseases with high unmet needs.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel therapeutics for immunological, inflammatory, and cardiometabolic diseases.
Features
- Genomics-based target discovery platform focused on bat DNA analysis
- Identification of therapeutic targets for immunological, inflammatory, and cardiometabolic diseases
- Mimicking bat's natural disease resistance for human therapeutic development
- Leveraging evolutionary insights to accelerate drug discovery